- Home
- CCCC vs CHEB Comparison
CCCC vs CHEB Comparison
Compare CCCC & CHEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- CHEB
- Stock Information
- Founded
- CCCC 2015
- CHEB 2024
- Country
- CCCC United States
- CHEB Singapore
- Employees
- CCCC N/A
- CHEB N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- CHEB
- Sector
- CCCC Health Care
- CHEB
- Exchange
- CCCC Nasdaq
- CHEB NYSE
- Market Cap
- CCCC 115.0M
- CHEB 122.8M
- IPO Year
- CCCC 2020
- CHEB 2024
- Fundamental
- Price
- CCCC $1.47
- CHEB $9.80
- Analyst Decision
- CCCC Buy
- CHEB
- Analyst Count
- CCCC 3
- CHEB 0
- Target Price
- CCCC $12.00
- CHEB N/A
- AVG Volume (30 Days)
- CCCC 943.9K
- CHEB 36.8K
- Earning Date
- CCCC 07-31-2025
- CHEB 01-01-0001
- Dividend Yield
- CCCC N/A
- CHEB N/A
- EPS Growth
- CCCC N/A
- CHEB N/A
- EPS
- CCCC N/A
- CHEB N/A
- Revenue
- CCCC $39,783,000.00
- CHEB N/A
- Revenue This Year
- CCCC N/A
- CHEB N/A
- Revenue Next Year
- CCCC N/A
- CHEB N/A
- P/E Ratio
- CCCC N/A
- CHEB N/A
- Revenue Growth
- CCCC 98.56
- CHEB N/A
- 52 Week Low
- CCCC $1.09
- CHEB $6.09
- 52 Week High
- CCCC $7.66
- CHEB $13.70
- Technical
- Relative Strength Index (RSI)
- CCCC 51.01
- CHEB N/A
- Support Level
- CCCC $1.21
- CHEB N/A
- Resistance Level
- CCCC $1.57
- CHEB N/A
- Average True Range (ATR)
- CCCC 0.12
- CHEB 0.00
- MACD
- CCCC 0.02
- CHEB 0.00
- Stochastic Oscillator
- CCCC 70.27
- CHEB 0.00
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.